

Appl. No. 10/701,498  
Amendment dated: June 17, 2005  
Reply to OA of: December 17, 2004

**Amendments to the Specification:**

On page 12, please add the following subheading before the first full paragraph and replace the six paragraphs thereafter with the following amended paragraphs.

**Brief Description of the Drawings**

The invention will now be illustrated further by the following non-limiting Examples and by reference to the Figures, in which:

Figure 1 shows the HIV antigen concentration in human CD4 cells infected with HIV and treated with 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) or phenbutazone (PB) at various concentrations;

Figure 2 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with AZT;

Figure 3 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with indinavir; [[and;]]

Figure 4 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with nevirapine; and

Figure 5 shows a 4OH-OPB acting together with 2',3'-dideoxyinosine (DDI);

A similar effect to those shown in figures 2-4 is seen when OPB is used in combination with 2',3'-dideoxyinosine (dal).